Corcept Therapeutics' stock has surged 52% in the past three months. Analyzing its ROE of 21%, which indicates efficient capital utilization, the company's growth potential is promising despite low net income growth. Future earnings growth and market valuation are key factors to consider for investors.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing